Subscribe to RSS
DOI: 10.1055/a-1724-7289
Point Shear Wave Elastography by ElastPQ for Fibrosis Screening in Patients with NAFLD: A Prospective, Multicenter Comparison to Vibration-Controlled Elastography
Punkt-Schwerwellen-Elastographie mittels ElastPQ für das Fibrosescreening in NAFLD Patienten: eine prospektive, multizentrische StudieSupported by: Philips Healthcare
Abstract
Background Since nonalcoholic fatty liver disease (NAFLD) has become the leading cause of liver disease in the Western world, clinicians need reliable noninvasive tools for the identification of NAFLD-associated fibrosis. Limited evidence on the performance of the novel shear wave elastography technique Elast-PQ (EPQ) in NAFLD is available. Method In this prospective, European multinational study we assessed the diagnostic accuracy of EPQ using vibration-controlled transient elastography (VCTE) as a reference standard. Results Among 353 NAFLD patients, 332 (94.1%) fulfilled reliability criteria of VCTE and EPQ (defined by IQR/median ≤0.3; 41.3% female, mean age: 59 [IQR: 16.5], mean BMI: 29.0 (7.1)). 4/353 (1.1%) and 17/353 (4.8%) had unreliable VCTE and EPQ measurements, respectively. VCTE-based NAFLD fibrosis stages were F0/F1: 222(66.9%), F2: 41 (12.3%), F3: 30 (9.1%), F4: 39 (11.7%). We found a strong correlation (Pearson R=0.87; p<0.0001) and concordance (Lin’s concordance correlation coefficient =0.792) of EPQ with VCTE. EPQ was able to identify NAFLD-fibrosis risk with the following EPQ cutoffs: ≥6.5 kPa for significant fibrosis (≥F2) (≥1.47 m/s; sensitivity: 78%; specificity: 95%; AUROC: 0.94), ≥6.9 kPa for advanced fibrosis (≥F3) (≥1.52 m/s; sens.: 88%, spec.: 89%; AUROC: 0.949), and ≥10.4 kPa for cirrhosis (F4) (≥1.86 m/s; sens.: 87%; spec.: 94%; AUROC: 0.949). Conclusion The point shear wave elastography technique EPQ shows excellent correlation to and concordance with VCTE. EPQ can reliably exclude NAFLD fibrosis <6.0 kPa (<1.41 m/s) and indicate a high risk of advanced fibrosis ≥10.4 kPa (≥1.86 m/s).
Zusammenfassung
Hintergrund Die nichtalkoholische Fettleber (NAFLD) ist mittlerweile die häufigste Lebererkrankung in der westlichen Welt. Daher besteht ein Bedarf an nichtinvasiven Methoden zur Einschätzung des Fibrose-Risikos bei NAFLD. Über die Aussagekraft der neue Scherwellen-Technologie Elast-PQ (EPQ) liegen nur wenige Daten vor. Methoden Diese prospektive, europäische multinationale Studie untersuchte die diagnostische Genauigkeit von EPQ bei NAFLD-PatientInnen im Vergleich zur Vibrations-kontrollierten transienten Elastografie (VCTE). Resultate Von 353 NAFLD-Patient*innen erfüllten 332 (94,1%) die Zuverlässigkeitskriterien für VCTE und EPQ (definiert als IQR/median ≤0,3). Die Studienpopulation war zu 41,3% weiblich, mit einem medianen Alter von 59 [IQR: 16,5] Jahren und einem medianen BMI von 29 [IQR: 7] kg/m2. Es bestand eine starke Korrelation (Pearson R=0,87; p<0.0001) und Konkordanz (Lin-Konkordanz-Korrelationskoeffizient=0,792) von EPQ mit VCTE. EPQ konnte das NAFLD-Fibrose-Risiko anhand folgender Grenzwerte abschätzen: Signifikante Fibrose (≥F2) ab ≥6,5 kPa (≥1,47 m/s; Sensitivität: 80%; Spezifität: 95%; AUROC: 0,940), fortgeschrittene Fibrose (≥F3) ab ≥6,9 kPa (≥1,52 m/s; Sensitivität: 88%, Spezifität: 89%; AUROC: 0,949), und Zirrhose (F4) ab ≥10,4 kPa (≥1,86 m/s; Sensitivität: 87%; Spezifität: 94%; AUROC: 0,949). Schlussfolgerungen Die Punkt-Scherwellen-Elastografie-Methode EPQ zeigt eine exzellente Korrektion und Konkordanz mit der VCTE. Bei NAFLD-Patient*innen wird durch EPQ <6,0 kPa (<1,41 m/s) eine signifikante Fibrose ausgeschlossen und durch EPQ ≥10,4 kPa (≥1,86 m/s) ein hohes Risiko für eine fortgeschrittene Fibrose angezeigt.
Publication History
Received: 07 April 2021
Accepted after revision: 08 December 2021
Article published online:
28 February 2022
© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Leite NC, Villela-Nogueira CA, Pannain VLN. et al. Histopathological stages of non-alcoholic fatty liver disease in type 2 diabetes: Prevalences and correlated factors. Liver Int 2011;
- 2 Younossi ZM, Koenig AB, Abdelatif D. et al. Global epidemiology of nonalcoholic fatty liver disease – Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;
- 3 Pimpin L, Cortez-Pinto H, Negro F. et al. Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies. Journal of Hepatology 2018;
- 4 Webber L, Divajeva D, Marsh T. et al. The future burden of obesity-related diseases in the 53 WHO European-Region countries and the impact of effective interventions: A modelling study. BMJ Open 2014;
- 5 Angulo P, Kleiner DE, Dam-Larsen S. et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015;
- 6 Semmler G, Scheiner B, Schwabl P. et al. The impact of hepatic steatosis on portal hypertension. PLoS One Public Library of Science 2019; 14: e0224506
- 7 Ferraioli G, Wong VWS, Castera L. et al. Liver Ultrasound Elastography: An Update to the World Federation for Ultrasound in Medicine and Biology Guidelines and Recommendations. Ultrasound Med Biol Elsevier USA 2018; 44: 2419-2440
- 8 Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 2014;
- 9 Dietrich CF, Bamber J, Berzigotti A. et al. EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Long Version). Ultraschall in Med 2017; 38: e16-e47
- 10 Chalasani N, Younossi Z, Lavine JE. et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;
- 11 Myers RP, Pomier-Layrargues G, Kirsch R. et al. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology 2012;
- 12 Ferraioli G, Tinelli C, Lissandrin R. et al. Point shear wave elastography method for assessing liver stiffness. World J Gastroenterol 2014;
- 13 Bucsics T, Grasl B, Ferlitsch A. et al. Point Shear Wave Elastography for Non-invasive Assessment of Liver Fibrosis in Patients with Viral Hepatitis. Ultrasound Med Biol 2018;
- 14 Sterling RK, Lissen E, Clumeck N. et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;
- 15 Schwabl P, Bota S, Salzl P. et al. New reliability criteria for transient elastography increase the number of accurate measurements for screening of cirrhosis and portal hypertension. Liver Int Blackwell Publishing Ltd 2015; 35: 381-390
- 16 Ferraioli G, de Silvestri A, Reiberger T. et al. Adherence to quality criteria improves concordance between transient elastography and ElastPQ for liver stiffness assessment – A multicenter retrospective study. Dig Liver Dis 2018;
- 17 Tsochatzis EA, Gurusamy KS, Ntaoula S. et al. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: A meta-analysis of diagnostic accuracy. J Hepatol Elsevier 2011; 54: 650-659
- 18 de Franchis R. Expanding consensus in portal hypertension. J Hepatol 2015; 63: 743-752
- 19 Reiberger T, Püspök A, Schoder M. et al. Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III). Wien Klin Wochenschr 2017;
- 20 Youden WJ. Index for rating diagnostic tests. Cancer 1950; 3
- 21 Leong WL, Lai LL, Nik Mustapha NR. et al. Comparing point shear wave elastography (ElastPQ) and transient elastography for diagnosis of fibrosis stage in non-alcoholic fatty liver disease. J Gastroenterol Hepatol Blackwell Publishing 2020; 35: 135-141
- 22 Semmler G, Binter T, Kozbial K. et al. Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease. Hepatology Wiley 2020;
- 23 Liu H, Fu J, Hong R. et al. Acoustic radiation force impulse elastography for the non-invasive evaluation of hepatic fibrosis in non-alcoholic fatty liver disease patients: A systematic review & meta-analysis. PLoS One Public Library of Science 2015; 10: e0127782
- 24 Lin Y, Li H, Jin C. et al. The diagnostic accuracy of liver fibrosis in non-viral liver diseases using acoustic radiation force impulse elastography: A systematic review and meta-analysis. PLoS One Public Library of Science 2020; 15: e0227358
- 25 Garcovich M, Stasio E Di, Zocco MA. et al. Assessing Baveno VI criteria with liver stiffness measured using a new point-shear wave elastography technique (BAVElastPQ study). Liver Int 2020;
- 26 Trebicka J, Gu W, Ledinghen V De. et al. Two-dimensional shear wave elastography predicts survival in advanced chronic liver disease. Gut 2021;
- 27 Stift J, Semmler G, Walzel C. et al. Transjugular aspiration liver biopsy performed by hepatologists trained in HVPG measurements is safe and provides important diagnostic information. Dig Liver Dis 2019;
- 28 Reiberger T, Schwabl P, Trauner M. et al. Measurement of the hepatic venous pressure gradient and transjugular liver biopsy. J Vis Exp 2020; 1-16
- 29 Grgurevic I, Salkic N, Bozin T. et al. Magnitude dependent discordance in liver stiffness measurements using elastography point quantification with transient elastography as the reference test. Eur Radiol Springer Verlag; 2019; 29: 2448-2456
- 30 Ferraioli G, de Silvestri A, Lissandrin R. et al. Evaluation of Inter-System Variability in Liver Stiffness Measurements. Ultraschall in Med 2018; 40: 64-75